Description: An Open-Label, Multicenter, Dose Escalation and Expansion Modular, Umbrella Master Study of Upifitamab Rilsodotin In Combination with Other Agents in Participants with High-Grade Serous Ovarian Cancer (Upgrade)
Target Patient Population: Platinum sensitive Ovarian Cancer
Study Design: Drug is given IV every 4 week